Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of LIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and BIBP Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) in Healthy Population Aged 18 and Above
Name
CNBG-REC-2022006
Description
This clinical trial adopts a randomized, double-blind and placebo-controlled design.
A total of 16000 participants are planned to be enrolled, of which, Cohort 1: 15000 participants vaccinated with ≥2 doses of inactivated COVID-19 vaccine for ≥6 months will be randomly administered at ratio of 1:1:1 with 1 dose of LIBP-Rec-Vaccine, BIBP-Rec-Vaccine or placebo intramuscularly to the deltoid muscle of upper arm.
Cohort 2: 1000 participants vaccinated with ≥2 doses of mRNA COVID-19 vaccine for ≥6 months will be randomly administered at ratio of 1:1 with 1 dose of LIBP-Rec-Vaccine or BIBP-Rec-Vaccine intramuscularly to the deltoid muscle of upper arm.
Trial arms
Trial start
2022-11-04
Estimated PCD
2023-10-01
Trial end
2023-12-01
Status
Recruiting
Phase
Early phase I
Treatment
LIBP-Rec-Vaccine
Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm
Arms:
Cohort 1 LIBP-Rec-Vaccine Group, Cohort 2 LIBP-Rec-Vaccine Group
BIBP-Rec-Vaccine
Intramuscular injection of BIBP-Rec-Vaccine in the deltoid muscle of the upper arm
Arms:
Cohort 1 BIBP-Rec-Vaccine Group, Cohort 2 BIBP-Rec-Vaccine Group
placebo
Intramuscular injection of placebo in the deltoid muscle of the upper arm
Arms:
Cohort 1 placebo control group
Size
16000
Primary endpoint
Cohort 1: Efficacy of LIBP-Rec-Vaccine/ BIBP-Rec-Vaccine against COVID-19 of immunization in healthy population aged 18 and above.
14th day after vaccination
Eligibility criteria
Inclusion Criteria:
* Age range: healthy population aged ≥18;
* Judged by the investigator that the health condition is well after inquiry and physical examination;
* Cohort 1: participants vaccinated with ≥2 doses of inactivated COVID-19 vaccines for ≥6 months since the last dose of vaccination; Cohort 2: participants vaccinated with ≥2 doses of mRNA COVID-19 vaccines for ≥6 months since the last dose of vaccination;
* Be able and willing to complete all prescribed study schedules during the whole study period;
* The participant himself/herself is able and willing to understand study procedures, sign the informed consent form voluntarily after informed consent and comply to requirements of the study protocol.
Exclusion Criteria:
* Symptomatic and suspected COVID 19 infection positive ;
* Urine pregnancy test is positive; Women of childbearing age who have positive urine pregnancy test, who are pregnant, lactating, or women who have planned pregnancy within 6 months;
* Auxiliary temperature before vaccination is ≥37.3℃ (tympanic/forehead temperature ≥37.8℃);
* Previous allergy history of vaccine vaccination (such as acute allergic reaction, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain, etc.) or allergy to known components of COVID-19 vaccine;
* Have a history of hospital-diagnosed thrombocytopenia or other coagulation disorders;
* With known immunological impairment or compromised immunological function diagnosed by the hospital;
* Received whole blood, plasma and immunoglobulin therapy within 1 month;
* Known or suspected of suffering from the following diseases: acute or chronic active respiratory diseases, severe cardiovascular diseases \[cardiopulmonary failure, hypertension uncontrollable by drugs (systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 95 mmHg)\], acute infection, active phase of chronic disease, liver and kidney diseases, severe diabetes, malignant tumor, infectious skin diseases or severe skin allergy, HIV infection, etc. (Examination report can be provided)
* Received live attenuated vaccine within one month before vaccination;
* Received inactivated vaccine within 14 days before vaccination;
* Other contraindications related to vaccination that investigators believe.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 16000, 'type': 'ESTIMATED'}}
Updated at
2022-11-10
1 organization
3 products
1 indication
Organization
National Vaccine and Serum InstituteProduct
LIBP-Rec-VaccineIndication
COVID-19Product
BIBP-Rec-VaccineProduct
placebo